This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lemström, K. Articles by Koskinen, P. Search for Related Content PubMed PubMed Citation Articles by Lemström, K. Articles by Koskinen, P.

(Circulation. 1997;95:2614-2616.)
© 1997 American Heart Association, Inc.

Articles

Cytomegalovirus Infection–Enhanced Cardiac Allograft Vasculopathy Is Abolished by DHPG Prophylaxis in the Rat

Karl Lemström, MD, PhD; Roope Sihvola, MD; Cathrien Bruggeman, PhD; Pekka Häyry, MD, PhD; Petri Koskinen, MD, PhD

From the Transplantation Laboratory, University of Helsinki, and Helsinki University Central Hospital, Finland.

Correspondence to Dr Karl Lemström, Transplantation Laboratory, PO Box 21 (Haartmaninkatu 3), FIN-00014 University of Helsinki, Finland. E-mail karl.lemstrom{at}helsinki.fi

Background A wealth of clinical and experimental evidence exists for cytomegalovirus (CMV) infection as an accelerating factor in the development of cardiac allograft vasculopathy. In this study, the impact of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) on rat CMV infection–enhanced cardiac allograft vasculopathy is investigated.

Methods and Results Heterotopic rat cardiac allografts were performed from the DA to the WF rat strain, and the recipients were immunosuppressed with cyclosporine A 2 mg·kg^-1·d^-1 SC for a period of 90 days until the end of experiment. Two groups of recipients were infected intraperitoneally with 10⁵ plaque-forming units of rat CMV, whereas one group was left noninfected and used as controls. One group of rat CMV–infected rats was treated with DHPG with an initial dose of 20 mg/kg IP and a maintenance dose of 10 mg/kg IP twice a day from 1 day before transplantation to 30 days after transplantation. Compared with noninfected rats, rat CMV infection was associated with a significant increase in intimal thickening, from 0.68±0.10 to 1.30±0.12 score units (P<.01), and double the number of vessels affected (P<.01). DHPG treatment significantly reduced intimal thickening in rat CMV–infected rats, from 1.30±0.12 to 0.68±0.13 score units (P<.01), and halved the number of vessels affected (P<.01).

Conclusions The present results demonstrate that DHPG prophylaxis entirely abolishes the accelerating effect of rat CMV infection on cardiac allograft vasculopathy in immunosuppressed rat recipients, which is consistent with our earlier findings demonstrating a similar effect in nonimmunosuppressed rat aortic allografts. Taken together, these results suggest that DHPG might be useful in the prevention of CMV-accelerated cardiac allograft vasculopathy among heart transplant recipients.

Key Words: transplantation • ganciclovir • viruses

This article has been cited by other articles:

				S. A. Webber Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in Children Circulation, April 3, 2007; 115(13): 1701 - 1702. [Full Text] [PDF]

				T. Hussain, M. Burch, M. J. Fenton, P. M. Whitmore, P. Rees, M. Elliott, and P. Aurora Positive Pretransplantation Cytomegalovirus Serology Is a Risk Factor for Cardiac Allograft Vasculopathy in Children Circulation, April 3, 2007; 115(13): 1798 - 1805. [Abstract] [Full Text] [PDF]

				M. Rahmani, R. P. Cruz, D. J. Granville, and B. M. McManus Allograft Vasculopathy Versus Atherosclerosis Circ. Res., October 13, 2006; 99(8): 801 - 815. [Abstract] [Full Text] [PDF]

				C. A. Bolovan-Fritts, R. N. Trout, and S. A. Spector Human Cytomegalovirus-Specific CD4+-T-Cell Cytokine Response Induces Fractalkine in Endothelial Cells J. Virol., December 1, 2004; 78(23): 13173 - 13181. [Abstract] [Full Text] [PDF]

				D. N. Streblow, C. Kreklywich, Q. Yin, V. T. De La Melena, C. L. Corless, P. A. Smith, C. Brakebill, J. W. Cook, C. Vink, C. A. Bruggeman, et al. Cytomegalovirus-Mediated Upregulation of Chemokine Expression Correlates with the Acceleration of Chronic Rejection in Rat Heart Transplants J. Virol., February 1, 2003; 77(3): 2182 - 2194. [Abstract] [Full Text] [PDF]

				M. GIRAL, J. M. NGUYEN, P. DAGUIN, M. HOURMANT, D. CANTAROVICH, J. DANTAL, G. BLANCHO, R. JOSIEN, D. ANCELET, and J. P. SOULILLOU Mycophenolate Mofetil Does Not Modify the Incidence of Cytomegalovirus (CMV) Disease after Kidney Transplantation but Prevents CMV-Induced Chronic Graft Dysfunction J. Am. Soc. Nephrol., August 1, 2001; 12(8): 1758 - 1763. [Abstract] [Full Text] [PDF]

				I. W. Fong Emerging relations between infectious diseases and coronary artery disease and atherosclerosis Can. Med. Assoc. J., July 1, 2000; 163(1): 49 - 56. [Abstract] [Full Text] [PDF]